Letters to the Editor

Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia

Hematology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford
New York-Presbyterian Columbia University Medical Center, New York, NY
Memorial Sloan Kettering Cancer Center, New York, NY,
Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center, Seattle, WA;
Dept. of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation,
Division of Hematology/Oncology, Wilmot Cancer Institute, University of Rochester, Rochester, NY
Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA;
Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC,
Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC,
Weill Cornell Medicine School of Medicine, Long Island City, NY;
Div. of Hematology and Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
Div of Hematology and Oncology,Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
Aptitude Health, Atlanta, GA,
Novant Health, Charlotte, NC,
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ,
Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC
Memorial Sloan Kettering Cancer Center, New York, NY,
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC,
Department of Medicine, Cancer Center, Tufts Medical Center, Boston, MA
Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA,
Department of Hematology, Lymphoma Division, Levine Cancer Institute, Charlotte, NC,
Dept of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation
Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Seattle, WA,
Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC,
Haematology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford,
Department of Haematology, Addenbrookes, Cambridge,
Nottingham University Hospitals NHS Trust, Nottingham,
Hematologic Malignancies and Cellular Therapy, Duke University Medical Center, Durham, NC,
Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center, Seattle, WA
Memorial Sloan Kettering Cancer Center, New York, NY
Vol. 106 No. 1 (2021): January, 2021 https://doi.org/10.3324/haematol.2019.241539